Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $1,037.33

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have received a consensus rating of “Moderate Buy” from the twenty-three analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $1,032.57.

Several equities research analysts have weighed in on REGN shares. Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd.

Regeneron Pharmaceuticals Stock Up 1.8 %

Shares of Regeneron Pharmaceuticals stock opened at $703.43 on Monday. The stock’s 50-day moving average is $746.43 and its 200 day moving average is $956.18. The firm has a market cap of $77.30 billion, a price-to-earnings ratio of 17.41, a PEG ratio of 2.19 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals has a one year low of $666.25 and a one year high of $1,211.20.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Fairfield Financial Advisors LTD purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $37,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $39,000. Finally, Truvestments Capital LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter worth approximately $39,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.